UK 12:48 Monday, 26 October 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
Prostate cancer lies twentieth in the ‘league table’ of annual cancer research spend. It kills slightly more men than breast cancer kills women but it gets half the funding. That’s why treatment lags ten years behind breast cancer and many years behind some other forms of cancer. Brian Basham is a legend among journalists
.
Brian was a great reporter on Fleet Street, a legendary PR spinner and a man who always has a fascinating tale over a glass of wine. He is also a friend of mine and a supporter of free speech and this website although he has a few odd views on matters such as Brexit. Anyhow the old boy is on a 10 mile training run as I write. Last weekend it was 16 miles. Next weekend it will be 18. And on 22 April it will be 26 miles 385 yards in the London Marathon.
I expect him to finish sometime on Monday morning just after the guy in the deep sea diving suit. But I am sure he will finish as he is running to raise money for prostate cancer. I normally only give to one charity (Woodlarks) but I take my hat off to someone as old as Brian doing this so will make a small donation to sponsor him this time. It is a good cause after all. If you wish to sponsor Brian you can do so HERE
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
